PT-141 (Bremelanotide) (PT141)

Metabolite of Melanotan II developed specifically for sexual dysfunction. FDA approved as Vyleesi for hypoactive sexual desire disorder.

Key Data

Research Status

FDA approved

Half-Life

2-4 hours

Administration

Subcutaneous injection

Typical Dosage

1.75 mg as needed

Mechanism of Action

MC3R and MC4R agonist that acts centrally to increase sexual desire without direct vascular effects.

Reported Benefits

• Sexual desire enhancement
• Works for both sexes
• Central mechanism
• FDA approved

All information is presented for Research Use Only (RUO). Not medical advice.